Unknown

Dataset Information

Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes.


ABSTRACT:

Background

Economic models in oncology are commonly based on the three-state partitioned survival model (PSM) distinguishing between progression-free and progressive states. However, the heterogeneity of responses observed in immuno-oncology (I-O) suggests that new approaches may be appropriate to reflect disease dynamics meaningfully.

Materials and methods

This study explored the impact of incorporating immune-specific health states into economic models of I-O therapy. Two variants of the PSM and a Markov model were populated with data from one clinical trial in metastatic melanoma patients. Short-term modeled outcomes were benchmarked to the clinical trial data and a lifetime model horizon provided estimates of life years and quality adjusted life years (QALYs).

Results

SUBMITTER: Gibson EJ 

PROVIDER: S-EPMC5848668 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature